Scherbaum N, Klein S, Kaube H, Kienbaum P, Peters J, Gastpar M
Department of Psychiatry and Psychotherapy, University Hospital, Essen, Germany.
Pharmacopsychiatry. 1998 Nov;31(6):205-9. doi: 10.1055/s-2007-979329.
This study was done in order to examine the hypothesis that so-called ultra-rapid opiate detoxification provides a mild, short, and safe withdrawal. A total of 22 patients who were addicted to opiates exclusively underwent ultra-rapid detoxification. Each patient was pretreated with methadone. During general anesthesia lasting about six hours with methohexital or propofol, naloxone was administered with doubling of the dose every 15 minutes with a starting bolus dose of 0.4 mg. The total bolus dose of 12.4 mg, delivered within 60 minutes, was followed by a naloxone infusion of 0.8 mg/h until the next morning. On the day of anesthesia naltrexone (50 mg/d) treatment was initiated. When withdrawal symptoms occurred, specific medications, e.g., clonidine, were added. After determining baseline values, withdrawal symptoms were investigated during a further four weeks by means of established clinical scales. The results document marked withdrawal symptoms for at least one week after detoxification. The intensity of withdrawal symptoms during the first seven days of treatment was significantly (p<0.05) more marked than during baseline. None of the patients underwent a life-threatening complication and only one patient failed to complete the detoxification procedure. Finally, about 75% of the patients could be referred for further treatment. In this study ultra-rapid detoxification provided a safe withdrawal procedure with high rates of completed withdrawals and referrals for further treatment, respectively. However, in contrast to previous reports, many patients suffered from middle-grade withdrawal symptoms over several days. Due to the risks of general anesthesia and the expense associated with this treatment, only patients addicted to opiates alone and for whom other detoxification strategies are unsuitable should undergo a ultra-rapid detoxification procedure.
本研究旨在检验所谓的超快速阿片类药物脱毒能提供轻度、短暂且安全的戒断反应这一假设。共有22名仅对阿片类药物成瘾的患者接受了超快速脱毒治疗。每位患者均先用美沙酮进行预处理。在使用美索比妥或丙泊酚持续约6小时的全身麻醉期间,给予纳洛酮,起始推注剂量为0.4毫克,每15分钟剂量加倍。在60分钟内给予的总推注剂量为12.4毫克,随后以0.8毫克/小时的速度输注纳洛酮直至次日早晨。在麻醉当天开始使用纳曲酮(50毫克/天)治疗。当出现戒断症状时,添加特定药物,如可乐定。在确定基线值后,通过既定的临床量表在接下来的四周内对戒断症状进行调查。结果表明,脱毒后至少一周内存在明显的戒断症状。治疗的前七天内戒断症状的强度明显(p<0.05)高于基线期。没有患者发生危及生命的并发症,只有一名患者未能完成脱毒程序。最后,约75%的患者可被转介接受进一步治疗。在本研究中,超快速脱毒提供了一种安全的脱毒程序,分别具有较高的完成脱毒率和转介接受进一步治疗率。然而,与先前的报告相反,许多患者在数天内出现中度戒断症状。由于全身麻醉的风险以及与该治疗相关的费用,仅对单独对阿片类药物成瘾且其他脱毒策略不适用的患者才应进行超快速脱毒程序。